Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Sep 6, 2011
Cambridge, MA – September 6, 2011 - Epizyme, Inc., a leader in the discovery and development of personalized therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics, announced today that it has been selected by the editors of FierceBiotech a...
Aug 31, 2011
Cambridge, MA, August 31, 2011 – Epizyme, Inc., a company leading the discovery and development of targeted therapeutics for genetically-defined cancer patients based on breakthroughs in the field of epigenetics, today announced its participation in three upcoming conferences being held the first week of September...
Jul 11, 2011
Cambridge, Massachusetts, July 11, 2011– Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer and rare disease patients, and its collaborators announced the publication in Cancer Cell of breakthrough research in the treatment of MLL-rea...
Jun 23, 2011
White Plains, NY and Cambridge, MA, June 23, 2011 - The Leukemia & Lymphoma Society (LLS) and Epizyme announced today that they will jointly support pre-clinical and Phase 1 development of Epizyme’s DOT1L-targeted histone methyltransferase inhibitor (HMTi) for Mixed Lineage Le...
Apr 27, 2011
Cambridge, MA, April 27, 2011 - Epizyme, Inc., a leader in the creation of personalized therapeutics based on breakthrough discoveries in the field of epigenetics, announced today the company has been identified as the #1 company nationwide in The Scientist's ...
Mar 10, 2011
Cambridge, MA, March 10, 2011 - Epizyme, Inc. announced today a worldwide partnership with Eisai Co., Ltd., Tokyo, Japan to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients. Under the terms of the agreement, Ep...
Feb 10, 2011
Cambridge, MA, February 10, 2011 - Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients based on breakthroughs in the field of epigenetics, today announced its participation in three upcoming conferences being held during February. ...
Jan 10, 2011
Cambridge, MA, January 10, 2011 – Epizyme today announced a worldwide strategic alliance with GlaxoSmithKline (GSK) to discover, develop, and market novel small molecule therapeutics targeting histone methyltransferases (HMTs), an important class of epigenetic enzymes, for the treatment of cancer and other diseases. ...
Jan 6, 2011
NORWALK, Conn. – January 6, 2011 - The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of...
Nov 23, 2010
Cambridge, MA, November 23, 2010 - Epizyme, Inc., a company creating personalized therapeutics based on breakthrough discoveries in the field of epigenetics, announced that data related to the Company’s programs will be the subject of multiple oral presentations at the 52nd American Society of Hematology (ASH) Annual Mee...
Nov 15, 2010
Cambridge, MA, November 15, 2010 - Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, today announced the publication of breakthrough new research in the Proceedings of the National Academy of Sciences (USA). The discovery, center...
Nov 3, 2010
Cambridge, MA, November 3, 2010 - Epizyme, Inc., a company leading the discovery and development of first‐in‐class, targeted cancer therapeutics against epigenetic targets, today announced that it has been awarded $733,437 in grants under the IRS Qualifying Therapeutic Discovery Project (QTDP). The grants are for t...
Jul 16, 2010
Cambridge, MA, July 16, 2010 - Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme...
May 14, 2010
Cambridge, MA, May 14, 2010 - Epizyme, Inc. announced today the appointment of Mikel Moyer, Ph.D., as Vice President of Molecular Discovery. He joins Epizyme from the Broad Institute, where he was Director of Medicinal Chemistry in the Stanley Center for Psychiatric Research. Prior to the Broad, Dr. Moyer held leadership posi...
Mar 24, 2010
Cambridge, MA, March 24, 2010 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceuticals, announced today the appointment of Robert Gould, Ph.D. as Chief Executive Officer and of Jason Rhodes as Executive Vice President and Chief Business Officer. Dr. Gould h...
= add release to Briefcase